HDAC6inhibition extends the safe rejuvenation window of transient OSK partial reprogramming by modulating heterochromatin dynamics at aging-associated enhancers

Hypothesis

Combining transient expression of the three Yamanaka factors (OSK) with periodic low-dose inhibition of histone deacetylase 6 (HDAC6) prolongs the epigenetic rejuvenation window while further reducing the risk of dedifferentiation or tumorigenesis.

Mechanistic Rationale

Partial reprogramming with OSK drives a steady decline in epigenetic age by opening chromatin at lineage‑appropriate enhancers and promoters, a process that precedes loss of somatic identity by several days [1][2]. However, the rejuvenating effect plateaus as heterochromatin reforms at aging‑associated loci, limiting the duration of beneficial epigenetic reset [4]. HDAC6 regulates cytoplasmic microtubule acetylation and also influences nuclear chromatin through deacetylation of H3K9 and H3K56, promoting heterochromatin formation [5]. Transient HDAC6 inhibition has been shown to maintain a more open chromatin state at enhancer regions without triggering pluripotency programs in fibroblasts [6]. We hypothesize that intermittent HDAC6 inhibition during OSK treatment will:

1. Sustain OSK‑induced chromatin accessibility at youth‑associated enhancers, thereby extending the decline in Horvath‑clock age beyond the typical 7‑day peak.
2. Delay the re‑accumulation of repressive H3K9me3 marks that signal the onset of dedifferentiation.
3. Reduce SASP‑mediated paracrine senescence signals that can arise from prolonged reprogramming, lowering tumorigenic risk.

Testable Predictions

• Prediction 1: In aged mice receiving doxycycline‑inducible OSK plus a weekly low‑dose HDAC6 inhibitor (e.g., tubastatin A), the Horvath‑clock epigenetic age will continue to decline for at least 21 days, whereas OSK‑only groups show a plateau after day 7 [4].
• Prediction 2: Lineage‑specific markers (e.g., RBPMS for retinal ganglion cells) will remain unchanged across the extended treatment period, confirming preserved identity.
• Prediction 3: Genome‑wide ATAC‑seq will reveal sustained accessibility at OSK‑targeted enhancers and reduced H3K9me3 signal at aging‑associated loci compared with OSK‑only.
• Prediction 4: Incidence of teratoma formation or hyperplasia in treated tissues will not exceed baseline levels observed with transient OSK alone.

Experimental Design

1. Animal model: 20‑month‑old C57BL/6J mice with Rosa26‑LSL‑OSK; rtTA transgene (dox‑inducible).
2. Treatment groups: (a) Vehicle control, (b) OSK only (2 mg/ml doxycycline 5 days on/2 days off), (c) OSK + low‑dose tubastatin A (5 mg/kg i.p. twice weekly), (d) HDAC6 inhibitor alone.
3. Readouts: Epigenetic age (Horvath mouse clock) via bisulfite sequencing at days 0, 7, 14, 21; immunofluorescence for lineage markers; ATAC‑seq and ChIP‑seq for H3K9me3/H3K27ac; SASP cytokine profiling (ELISA); histopathological examination for hyperplasia or tumors.
4. Statistical analysis: Two‑way ANOVA with post‑hoc Tukey test; significance set at p<0.05.

Potential Outcomes and Interpretation

If the data confirm Prediction 1‑3, we will have demonstrated that HDAC6 inhibition epigenetically "locks in" the youthful chromatin state initiated by OSK, thereby extending the therapeutic window without compromising identity. Failure to observe extended age reversal would suggest that heterochromatin re‑formation is not the limiting factor, prompting investigation of other chromatin regulators (e.g., SIRT1, EZH2). Observed increase in tumorigenic signals would indicate that prolonged chromatin openness exceeds safety thresholds, refining the dosing schedule for HDAC6 inhibition.

Implications

This hypothesis links two mechanistically distinct modalities—transient reprogramming and HDAC6‑mediated chromatin modulation—to improve the safety and efficacy of epigenetic rejuvenation therapies. Success could inform clinical protocols that pair doxycycline‑inducible OSK vectors with intermittent HDAC6 inhibitor administration, maximizing age‑reversal benefits while minimizing dedifferentiation risk, a critical step toward translating partial reprogramming into human therapeutics.

[1] https://doi.org/10.1111/acel.12877 [2] https://www.fightaging.org/archives/2026/02/the-first-clinical-trial-of-partial-reprogramming-will-start-soon/ [3] https://doi.org/10.1038/s41586-020-2975-4 [4] https://pmc.ncbi.nlm.nih.gov/articles/PMC12839720/ [5] https://cellura.io/partial-cellular-reprogramming-resetting-cellular-age-without-erasing-identity/ [6] https://www.hubmeded.com/blog/epigenetic-reprogramming